Breaks Categories: News

WednesdayJun 18, 2025 11:39 am

PsychedelicNewsBreaks – Psyence Biomedical Ltd. (NASDAQ: PBM) to Present at Psychedelic Science 2025

Psyence Biomed (NASDAQ: PBM) has announced that its Chief of Global Impact, Mary-Elizabeth Gifford, was selected as a featured speaker at Psychedelic Science 2025 (“PS2025”) – the world's largest international gathering focused on psychedelic research, biopharma, medicine, policy, and culture. Hosted by the Multidisciplinary Association for Psychedelic Studies (“MAPS”), the highly anticipated conference is taking place June 16-20, 2025, in Denver, Colorado. Psyence BioMed will present on business ethics in a panel session, “We are the Guardrails: Profit with Purpose.” In the role of Chief of Global Impact for Psyence Biomed, the first Nasdaq-listed biopharma with a focus on developing…

Continue Reading

MondayJun 16, 2025 9:20 am

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its subsidiary HOPE Therapeutics announced a strategic investor relations partnership with astr partners, a boutique firm specializing in life sciences. The collaboration comes as NRx advances toward two NDA filings, an ANDA submission, and expands its interventional psychiatry clinic acquisitions. Led by veterans of The Trout Group, astr will support NRx and HOPE with investor targeting, message development, earnings prep, and institutional outreach to enhance visibility and engagement. To view the full press release, visit https://ibn.fm/Frllm About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on…

Continue Reading

ThursdayJun 12, 2025 9:10 am

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics to Present at H.C. Wainwright Neuro Perspectives Conference

NRx Pharmaceuticals (NASDAQ: NRXP) and its wholly owned subsidiary HOPE Therapeutics, Inc. announced participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, set for June 16–17, 2025. Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx and Co-CEO of HOPE, will deliver a corporate presentation highlighting recent developments, available on demand to registered attendees starting at 7 a.m. ET on June 16. The company will also conduct one-on-one investor meetings during the event. To view the full press release, visit https://ibn.fm/ZyJ5Z About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA…

Continue Reading

ThursdayJun 05, 2025 1:19 pm

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine, Targets Expanding $750M Market 

  NRx Pharmaceuticals (NASDAQ: NRXP), has submitted an Abbreviated New Drug Application (ANDA) to the FDA for NRX-100, its preservative-free intravenous ketamine formulation aimed at approved indications such as anesthesia and pain management. With the U.S. ketamine market valued at $750 million and global demand projected to reach $3.35 billion by 2034, the company is seeking priority review amid an ongoing national shortage. NRx also plans to petition the FDA to mandate preservative-free ketamine formulations, citing safety concerns over benzethonium chloride. This filing complements its broader strategy to expand ketamine’s label to include treatment for suicidal depression, backed by clinical…

Continue Reading

TuesdayJun 03, 2025 10:50 am

PsychedelicNewsBreaks – Rythmia Life Advancement Center Unveils Affiliate Program for Wellness Advocates

Rythmia Life Advancement Center, the world’s first medically licensed ayahuasca retreat, has launched an affiliate program inviting wellness influencers, healers, and purpose-driven marketers to promote its transformational experiences. Based in Guanacaste, Costa Rica, Rythmia has welcomed over 15,000 guests with its unique integration of plant medicine, modern therapy, and spiritual healing. The new program offers partners competitive commissions, second-tier earnings, real-time tracking tools, and access to high-converting marketing assets. With a 95.12% guest-reported miracle rate, the initiative gives aligned partners a way to share Rythmia’s impact while earning income. CEO Gerard Powell emphasized the program’s mission to reward those spreading…

Continue Reading

WednesdayMay 28, 2025 2:30 pm

PsychedelicNewsBreaks – Lophora ApS Doses First Subjects in Phase 1 Trial of Psychedelic-Based CNS Drug LPH-5 

Lophora, a Danish biotech advancing next-generation psychedelic therapies, announced the first subjects have been dosed in its Phase 1 clinical trial of LPH-5, a novel serotonergic compound targeting central nervous system disorders. The trial, conducted by Biotrial in Rennes, France, is evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of both single and multiple ascending doses in healthy volunteers.  LPH-5 is engineered for targeted serotonin receptor engagement and designed to provide therapeutic benefits without the hallucinogenic effects commonly associated with traditional psychedelics. A preliminary data review is scheduled for June 17, 2025, with topline results expected in Q4. Company executives described the…

Continue Reading

WednesdayMay 21, 2025 9:00 am

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Wall Street Conference on May 21

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that Founder and CEO Dr. Jonathan Javitt will deliver a company update at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida. NRx is one of six companies invited to present at the high-profile event, which is expected to draw more than 1,000 attendees representing over $1 trillion in investment capital. The presentation will highlight the company’s progress toward FDA approval of NRX-100, a preservative-free intravenous ketamine formulation, as well as its strategic acquisition plans for HOPE clinics focused on treating suicidal depression, PTSD, and related conditions. To…

Continue Reading

FridayMay 16, 2025 9:00 am

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup 

NRx Pharmaceuticals (NASDAQ: NRXP) reported a Q1 2025 net loss of $5.5 million, down from $6.5 million in the same period last year, with operating losses narrowing to $3.8 million. The company advanced regulatory and commercial milestones for its two lead programs: NRX-100, a preservative-free IV ketamine formulation for suicidal depression now supported by an NDA fee waiver and new patent filing; and NRX-101, an oral treatment for bipolar depression with a PDUFA date anticipated before year-end. Subsidiary HOPE Therapeutics also gained momentum with $10.3 million in new acquisition funding to support a national psychiatry clinic rollup. NRx ended the…

Continue Reading

ThursdayMay 15, 2025 12:30 pm

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Secures $7.8M to Launch Clinic Rollup Strategy

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a term sheet with Universal Capital, LLC for $7.8 million in acquisition funding to support the rollout of its national interventional psychiatry clinic network. Combined with previously announced investments, HOPE now has $10.3 million in capital to execute initial acquisitions of Dura Medical, Kadima, and NeuroSpa. These clinics offer neuroplastic treatments such as ketamine and transcranial magnetic stimulation to treat severe depression and PTSD, with current contracts in place to serve veterans through the VA. Universal Capital expects to participate in future funding rounds as HOPE…

Continue Reading

WednesdayMay 14, 2025 3:41 pm

PsychedelicNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE’s Strategic Kadima Agreement

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is scheduled to report its first quarter 2025 financial results after the market closes on Thursday, May 15. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company’s investor relations site or by dialing +1-800-717-1738 (U.S.) or +1-646-307-1865 (international).  The earnings update comes shortly after news that NRx’s wholly owned subsidiary, HOPE Therapeutics, signed a definitive agreement to acquire Kadima Neuropsychiatry Institute in La Jolla, California. Kadima is a profitable clinic and leader in psychedelic and neuroplastic research, offering treatments for suicidal depression, PTSD and other CNS conditions. It is…

Continue Reading